Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Name: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
Published: 2021
License: Public Domain

Centre Leon Berard · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

nivolumab progression-free-survival

sarcoma, sarcoma of rare subtype, metastatic sarcoma, unresectable advanced sarcoma, nivolumab, ipilimumab, randomization, pazopanib, progression free-survival, best overall response, objective response rate, duration of response

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 887833
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.